FBL-MTX / Solfarcos - LARVOL DELTA

FBL-MTX-201: Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - P2 | N=40 | Active, not recruiting | Sponsor: SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2025 ➔ Jun 2026 | Trial primary completion date: Jul 2025 ➔ Jun 2026

Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd

New P2 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP